Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company maintains a strong financial position with a negligible Debt Equity Ratio of 0.01. Focus is on optimizing inventory and reducing sundry debtors to support future projects and business prospects. CapEx plans are mainly related to capacity expansion and technology development, but funding sources are not specified as new fundraising. No explicit discussion about raising funds through equity or additional debt during the call.

Future growth expectations in sales/revenue/volumes?

Company expects positive growth in sales and volumes in the current year driven by improved market demand and price realizations. Focus on achieving about 10% profit margins typical for the year. Expansion plans with new capacity additions primarily in the subsequent year. Increased export volumes, especially in manufacturing division, supported by EU and Turkey REACH registrations, boosting exports and revenues. New orders for N-Methylol Acrylamide (NMA) from multinational and domestic customers expected to substantially increase volumes. Commercial launch of Polyacrylamide Solids t

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is striving to achieve about 10% margins for the current year, which aligns with their typical margin levels. Positive revenue growth is expected due to improving market demand and price realizations, particularly from exports and manufacturing divisions. Manufacturing segment shows promise with new EU REACH and Turkey REACH registrations expanding export markets. Capacity expansions are planned, with new manufacturing plants targeted for early FY26, indicating planned future growth. Margins in manufacturing are expected to be better than distribution, supporting higher pro

Current/ Expected Orderbook/ Pending Orders?

The webinar transcript does not disclose specific details about the current or expected order book and pending orders in exact numbers. However, it mentions receiving new orders for N-Methylol Acrylamide (NMA) from a foreign multinational, indicating growth in that product line. Approval from a key domestic customer for NMA is expected soon, which is anticipated to substantially increase volume and sales. Discussions are ongoing for a new specialty chemicals manufacturing project with a key principal at the Jhagadia site. The company has earned two toll manufacturing projects with U.S. and Eur

Black Rose Industries LtdQ1 FY24Chemicals & Petrochemicals

Black Rose Industries Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹110P/E: 20.6Market Cap: ₹591 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

Company expects positive growth in sales and volumes in the current year driven by improved market demand and price realizations.
Focus on achieving about 10% profit margins typical for the year.
Expansion plans with new capacity additions primarily in the subsequent year.
Increased export volumes, especially in manufacturing division, supported by EU and Turkey REACH registrations, boosting exports and revenues.
New orders for N-Methylol Acrylamide (NMA) from multinational and domestic customers expected to substantially increase volumes.
Commercial launch of Polyacrylamide Solids targeted by Q3 FY25, expected to add to revenue streams.
Despite challenges like Chinese dumping affecting domestic sales, exports and better price realizations should drive growth.
Emphasis on maximizing revenues and profit over mere capacity utilization for new product lines.
Overall good growth expected in both distribution and manufacturing divisions compared to previous periods.

Margin guidance

Category 3

The company is striving to achieve about 10% margins for the current year, which aligns with their typical margin levels.
Positive revenue growth is expected due to improving market demand and price realizations, particularly from exports and manufacturing divisions.
Manufacturing segment shows promise with new EU REACH and Turkey REACH registrations expanding export markets.
Capacity expansions are planned, with new manufacturing plants targeted for early FY26, indicating planned future growth.
Margins in manufacturing are expected to be better than distribution, supporting higher profitability.
Despite current sector distress and pricing pressures, the company anticipates better price realizations towards the end of the quarter and subsequent periods.
Overall EBITDA improved significantly from 4.5% to 8.84% in recent quarter, with expectations to maintain or improve margins going forward.
The company foresees strong growth in volumes and revenues, especially in acrylamide-related products and downstream derivatives.

See what Black Rose Industries Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned fundraising through debt or equity in the transcript.
The company maintains a strong financial position with a negligible Debt Equity Ratio of 0.01.
Focus is on optimizing inventory and reducing sundry debtors to support future projects and business prospects.
CapEx plans are mainly related to capacity expansion and technology development, but funding sources are not specified as new fundraising.
No explicit discussion about raising funds through equity or additional debt during the call.

Order book

The webinar transcript does not disclose specific details about the current or expected order book and pending orders in exact numbers.
However, it mentions receiving new orders for N-Methylol Acrylamide (NMA) from a foreign multinational, indicating growth in that product line.
Approval from a key domestic customer for NMA is expected soon, which is anticipated to substantially increase volume and sales.
Discussions are ongoing for a new specialty chemicals manufacturing project with a key principal at the Jhagadia site.
The company has earned two toll manufacturing projects with U.S. and European companies.
Export sales are strengthening due to EU REACH and Turkey REACH registrations, supporting order inflow.
Overall, growth in orders is expected, especially in distribution and manufacturing divisions, but no exact figures are provided.

See what Black Rose Industries Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

- The company is developing new technology for Polyacrylamide Solids with a target commercial launch by Q3 FY25; CapEx estimated between ₹60 to ₹100 crores depending on finalized technology and equipment sourcing. - A specialty chemical manufacturing project in collaboration with a Japanese principal is in advanced discussion; no fresh land purchase needed, site identified at Jhagadia. - Toll manufacturing projects for U.S. and European companies in acrylamide-related products are underway, requiring additional CapEx. - Facility for manufacturing carboxylic acid is already available; only process/technology development is needed, involving no capital investment. - New capacity additions for other products are expected in subsequent years; current year focuses on market demand and price improvements. - CapEx is planned but balanced against margins and market realities; typical target margin of about 10% for the year. Overall, strategic investments focus on expanding manufacturing capabilities in specialty chemicals and related products with moderate CapEx and leveraging existing infrastructure.

Track Black Rose Industries Ltd — get its next earnings analysis in your feed

How does Black Rose Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBlack Rose Industries Ltd

Rev 4Mar 3

See where Black Rose Industries Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Black Rose Industries Ltd rank in Chemicals & Petrochemicals?

Compare Black Rose Industries Ltd against every Chemicals & Petrochemicals company (Q1 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Black Rose Industries Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →